Grupo Supervielle S.A. (NYSE:SUPV)
Grupo Supervielle S.A. (NYSE:SUPV) represented a move of 0 percent or $0.05 per share and closed its previous day trading session at $9. 0 Shares were traded in the last trading session with an Average Volume of 1.25 Million Shares. The stock currently has a Market Capitalization of 589.23 Million.
Grupo Supervielle SA is a private domestically-owned financial group primarily in Argentina. The Company owns Banco Supervielle S.A., an Argentine private domestically-owned bank which operates primary in the City of Buenos Aires and the Greater Buenos Aires metropolitan area, Mendoza and San Luis. Grupo Supervielle SA is based in Bueno Aires, Argentina.
The stock traded between $ 4.91 and $33.85 over 1-Year time period showing its price to sales ratio of 1.3. Grupo Supervielle S.A. (NYSE:SUPV) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $10.99 and 200-Day Simple Moving Average of $-43.96. Its Price to Free Cash Flow is 2.01 and Price to Book of 2.02.
Analyst’s recommended the stock as 2.2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Grupo Supervielle S.A. (NYSE:SUPV) reported its Actual EPS of $0.13/share. The analysts offering Earnings Estimates for the company were believing that Grupo Supervielle S.A. could bring EPS of $0.48/share. The difference between Actual EPS and Estimated EPS was -0.35 Percent. Thus showing an Earnings Surprise of -72.9 Percent.
Immutep Limited (NASDAQ:IMMP)
In the last trading session, Immutep Limited (NASDAQ:IMMP) added its value by 0% closing at the price of $2.72. The stock currently has market capitalization of 8.23 Billion, with average volume of 148.39 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Immutep Limited (NASDAQ:IMMP) is showing beta of 0. This particular value of beta suggests that Immutep Limited (NASDAQ:IMMP) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Immutep Limited (NASDAQ:IMMP) is at $-0.4.
The stock currently has RSI of 43.15. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company’s product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Immutep Limited (NASDAQ:IMMP) topped its 52-week high price of $4.21 on 10/01/18 and 52-Week Low Price of $1.25 on 12/26/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.13% and monthly volatility of 5.82% respectively.